The abstract submission system is now open
Abstract submission deadlines
Abstracts |
Deadline |
|---|---|
|
Abstracts Trial in Progress Intent to submit LBA |
Tuesday, 13 February 2024, 21:00 CET |
Late-breaking abstracts (LBA) |
Wednesday, 17 April 2024, 21:00 CEST |
Outcome notifications
Outcome notifications of regular abstracts are expected to be made available to first authors and submitters by end-March 2024.
Outcome notifications of accepted full LBAs are expected to be made available to first authors and submitters by end-April 2024.
Information for presenters
Detailed instructions for the preparation of slide presentations and/or posters will be made available by end-March in the section “Information for Presenters”.
Abstract submission categories
- Biomarkers and translational research and precision medicine
- Early breast cancer: Systemic treatments
- Early breast cancer: Surgery and radiotherapy
- Early detection, hereditary breast cancer and prevention
- Metastatic breast cancer
- Supportive care and survivorship
- Miscellaneous
Late-breaking abstracts
Late-breaking abstracts may be submitted for high quality, new research findings with implications for clinical practice or understanding of disease processes.
The final late-breaking abstract deadline of 17 April 2024 is under no circumstances to be considered as an extension of the general submission deadline (13 February 2024).
Trial in Progress abstracts
Trial in Progress (TiP) abstracts in all phases of clinical research (phases I to III) may be submitted to ESMO Breast Cancer 2024.
It is expected that abstracts submitted as Trial in Progress are ongoing trials that have not reached any protocol-specified endpoints for analysis.
Presentation and publication of accepted abstracts
The Breast Cancer 2024 Scientific Committee will select abstracts for presentation during the Congress and determine the format of the presentations from the following possibilities:
- Proffered Paper – Oral presentations by authors presenting original data of superior quality, followed by expert discussion and perspectives.
- Mini Oral – Short oral presentations by authors presenting data of good quality, followed by expert discussion and perspectives.
- Poster – Display session for review, discussion and questions. The presenting authors must be available for Q&A to represent their work.
All accepted abstracts, including Late-breaking, will be published online in the ESMO Breast Cancer 2024 Abstract Book, a supplement to the official ESMO journal, ESMO Open.
Publication schedule of accepted abstracts
Abstracts accepted for presentation during the ESMO Breast Cancer 2024 will be released online according to a schedule which will be available on the ESMO website in due course.
ESMO Merit Travel Grant
A restricted number of ESMO Merit Travel Grants to the ESMO Breast Cancer 2024 are available, upon application, to first author (= presenter) who submit abstracts considered to be deserving of recognition. Candidates must be ESMO Members under the age of 40. Selection will be made by the ESMO Breast Cancer 2024 Scientific Committee on a competitive basis from among the accepted abstracts.